合伙人
杨烨烨博士专注于美国地区法院的复杂专利诉讼业务,以及化学、制药和生物技术领域的双方复审(IPR)程序。杨博士有代表大型药物专利持有制药公司进行Hatch-Waxman诉讼的经验,并且为制药行业的客户多次起草联邦巡回上诉法院上诉人和被上诉人申诉书。杨博士因其在专利法领域的卓越表现而被Best Lawyers 机构列为" Ones to Watch最引人瞩目"律师。
杨博士处理过诉讼准备相关的各个环节,包括一般性证据开示、对关键证人的取证和动议程序,以及其他诉讼前尽职调查,如分析全球专利申请审批过程和专利强度、考察可能的专家和起草诉讼综述分析报告等。杨博士曾参与过IPR程序的多个环节,包括确定关键论点、准备和参加专家质证、起草专家报告、专利所有人答复和动议书,以及准备口头辩论等。此外,她还为生物技术领域的许可、收购、自由运作和创业融资等项目进行了大量尽职调查分析和为制药公司的全球专利布局和申请策略提供咨询服务。
杨博士拥有分子生物学和癌症生物学科学背景。在研究生期间,杨博士的研究集中于神经系统发育过程中识别涉及轴突导向的新基因,她的新发现发表在同行评议的科学杂志上。在Dana-Farber癌症研究所进行博士后研究期间,杨博士研究了表观遗传染色质重塑复合物,并发现了在细胞转化和肿瘤发生过程中与癌基因发生相互作用的肿瘤抑制候选基因。
在法学院就读期间,杨博士还密切关注了中国知识产权法的发展。杨博士在同行评议的法律期刊上发表了多篇有关中国专利法的文章。
Grünenthal GmbH et al. v. Actavis Elizabeth LLC et al.
Member of team that represented Grünenthal GmbH in multiple Hatch-Waxman suits involving analgesic drugs Nucynta® and Nucynta® ER; the district court enjoined the defendants from marketing generic versions until patent expiry.
2:13-cv-04507, -06929, -07803; 2:14-cv-03941, -04617; 2:15-cv-06797, D.N.J., Judges Cecchi, Falk
Eli Lilly and Company v. Actavis Labs. UT Inc.
Member of team representing Eli Lilly in Hatch-Waxman action against several defendants relating to Cialis®.
1:16-cv-01119, E.D. Va., Judges Nachmanoff, Trenga
Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Member of team representing Eli Lilly in an appeal from a Patent Trial and Appeal Board (PTAB) decision in an IPR case.
IPR2014-00693, -00752, PTAB, Judges Green, Prats, Snedden
16-1547, Fed. Cir., Judges Bryson, Moore, Newman
AstraZeneca LP v. SigmaPharm Laboratories
Member of team representing AstraZeneca in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.
1:15-cv-01000, D. Del., Judge Andrews
Actelion Pharmaceuticals v. ICOS Corp.
Member of team representing ICOS in two IPRs defending their formulation patents.
IPR2015-00561, -00562, PTAB, Judges Mitchell, Snedden, Yang
Eli Lilly and Company v. Teva Pharmaceuticals International
Member of team representing Eli Lilly in multiple IPRs involving antibody patents.
IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Event
Biosimilars and Interchangeable Biologics: New FDA Draft Guidance Clarifying Application Process for Approval Biosimilars and Interchangeable Biologics: New FDA Draft Guidance Clarifying Application Process for Approval
November 28, 2023
Webinar
Event
Secondary Patents on Both Sides of the Pond: Impact of Clinical Trials on Patentability Secondary Patents on Both Sides of the Pond: Impact of Clinical Trials on Patentability
November 2, 2023
Webinar
Event
Patent Drafting for Multiple Jurisdictions Patent Drafting for Multiple Jurisdictions
October 11, 2023
Webinar
2014年获Chris Bartok专利法纪念奖。
2014年在乔治华盛顿大学法院的Giles S. Rich IP模拟法庭竞赛中进入半决赛。
2013年在Marcus B. Finnegan知识产权写作竞赛中获第三名。
2013年在乔治华盛顿大学法院的Giles S. Rich IP模拟法庭竞赛中进入四分之一决赛。
2004年获William King Candlin杰出高年级研究生纪念助学金。
2003年获Twomey生理学和细胞生物学优秀成绩纪念奖。
2014年获Chris Bartok专利法纪念奖。
2014年在乔治华盛顿大学法院的Giles S. Rich IP模拟法庭竞赛中进入半决赛。
2013年在Marcus B. Finnegan知识产权写作竞赛中获第三名。
2013年在乔治华盛顿大学法院的Giles S. Rich IP模拟法庭竞赛中进入四分之一决赛。
2004年获William King Candlin杰出高年级研究生纪念助学金。
2003年获Twomey生理学和细胞生物学优秀成绩纪念奖。
Commentary
Fed. Circ. OKs Boston Drug Developer's Patent Win Fed. Circ. OKs Boston Drug Developer's Patent Win
March 11, 2024
Law360Press Release
Finnegan Announces 2024 Partner Class Finnegan Announces 2024 Partner Class
January 2, 2024
Press Release
32 Finnegan Attorneys Recognized by Best Lawyers 32 Finnegan Attorneys Recognized by Best Lawyers
August 17, 2023
Best LawyersPress Release
ITC Determines Healthgen’s Medium Grade Products Did Not Infringe Ventria’s Patent ITC Determines Healthgen’s Medium Grade Products Did Not Infringe Ventria’s Patent
September 16, 2022
Press Release
29 Finnegan Attorneys Ranked by Best Lawyers 29 Finnegan Attorneys Ranked by Best Lawyers
August 18, 2022
U.S. News—Best Lawyers
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.